https://mindmedicinelaw.com/briefing/epa-snurs-under-tsca-impact-on-psychedelic-research-industry-20261015-50220The Psychedelic Journalen2026-10-15T15:08:39.386617+00:00EPA SNURs Under TSCA: Impact on Psychedelic Research & Industryepa snur, tsca, psychedelic research regulation, chemical precursors, compliance risk, novel psychoactive substances, import restrictions, regulatory review, drug development, federal registerhttps://mindmedicinelaw.com/briefing/group-psilocybin-retreats-social-connection-outcomes-and-policy-implications-20261014-50269The Psychedelic Journalen2026-10-15T15:10:09.843915+00:00Group Psilocybin Retreats: Social Connection Outcomes and Policy Implicationspsilocybin retreat, group psychedelic therapy, social connectedness, clinical trials, psychedelic policy, retreat safety, group facilitation, distress reduction, psychedelic research, community-based carehttps://mindmedicinelaw.com/briefing/participant-advocacy-insights-for-psychedelic-trials-uk-global-policy-implicatio-20261014-50234The Psychedelic Journalen2026-10-15T15:09:47.783659+00:00Participant Advocacy Insights for Psychedelic Trials: UK & Global Policy Implicationspsychedelic clinical trials, participant advocacy, trial design, integration support, psilocybin, dmt, ethics, peer support, regulatory policy, mental health researchhttps://mindmedicinelaw.com/briefing/esketamine-as-adjunct-analgesia-dose-finding-rct-in-chinese-lumbar-surgery-20261014-50272The Psychedelic Journalen2026-10-15T15:09:25.848900+00:00Esketamine as Adjunct Analgesia: Dose-Finding RCT in Chinese Lumbar Surgeryesketamine, opioid-sparing, lumbar decompression surgery, perioperative analgesia, randomized controlled trial, dose finding, patient-controlled intravenous analgesia, sufentanil, multimodal pain management, adverse effectshttps://mindmedicinelaw.com/briefing/psilocybin-therapy-aftercare-standards-gap-in-oregon-colorado-20261014-50273The Psychedelic Journalen2026-10-15T15:09:03.905018+00:00Psilocybin Therapy Aftercare: Standards Gap in Oregon & Coloradopsilocybin therapy, integration, aftercare, oregon psilocybin services, colorado natural medicine act, clinical trial protocols, public health policy, regulatory standards, psychedelic researchhttps://mindmedicinelaw.com/briefing/ai-powered-mapping-of-psychedelic-clinical-trials-global-registry-insights-20261014-50271The Psychedelic Journalen2026-10-15T15:08:13.817185+00:00AI-Powered Mapping of Psychedelic Clinical Trials: Global Registry Insightspsychedelic clinical trials, ai in clinical research, clinicaltrials.gov, psilocybin trials, mdma trials, registry data analysis, trial methodology, global research disparities, systematic review, llm-powered synthesishttps://mindmedicinelaw.com/briefing/dea-maintains-schedule-i-status-for-mgm-15-and-mgm-16-in-the-us-20261014-49838The Psychedelic Journalen2026-10-14T15:05:23.333983+00:00DEA Maintains Schedule I Status for MGM-15 and MGM-16 in the USdea scheduling, mgm-15, mgm-16, kratom analogs, schedule i controlled substances, federal register, research barriers, controlled substances act, regulatory policy, mitragynine analogshttps://mindmedicinelaw.com/briefing/dea-temporarily-schedules-key-kratom-alkaloids-above-threshold-20261014-49837The Psychedelic Journalen2026-10-14T15:05:02.982651+00:00DEA Temporarily Schedules Key Kratom Alkaloids Above Thresholddea scheduling, kratom alkaloids, 7-hydroxymitragynine, mitragynine pseudoindoxyl, controlled substances act, threshold scheduling, research barriers, market impact, federal policy, psychoactive regulationhttps://mindmedicinelaw.com/briefing/psilocybin-and-norbaeocystin-acute-anxiety-effects-in-rats-20261013-50236The Psychedelic Journalen2026-10-15T15:11:08.214281+00:00Psilocybin and Norbaeocystin: Acute Anxiety Effects in Ratspsilocybin, norbaeocystin, anxiogenic effects, preclinical study, sex differences, acute adverse effects, clinical trial design, psychedelic safety, rodent modelshttps://mindmedicinelaw.com/briefing/ai-driven-pharmacovigilance-for-neuropsychiatric-drugs-fda-prospects-and-pitfall-20261013-50238The Psychedelic Journalen2026-10-15T15:10:52.266239+00:00AI-Driven Pharmacovigilance for Neuropsychiatric Drugs: FDA Prospects and Pitfallsai pharmacovigilance, fda drug safety, neuropsychiatric drugs, esketamine surveillance, psychedelic therapies, adverse event detection, natural language processing, regulatory decision-making, risk mitigation, real-world evidencehttps://mindmedicinelaw.com/briefing/intranasal-esketamine-for-treatment-resistant-depression-evidence-and-policy-imp-20261013-50282The Psychedelic Journalen2026-10-15T15:10:32.393754+00:00Intranasal Esketamine for Treatment-Resistant Depression: Evidence and Policy Implicationsesketamine, treatment-resistant depression, acute suicidality, intranasal administration, clinical trials, NMDA antagonist, psychiatric emergency care, adverse effects, policy implications, maintenance therapyhttps://mindmedicinelaw.com/briefing/rtms-response-varies-by-depressive-phenotype-preclinical-insights-20261013-50094The Psychedelic Journalen2026-10-14T22:07:25.644610+00:00rTMS Response Varies by Depressive Phenotype: Preclinical InsightsrTMS, treatment-resistant depression, phenotype-specific response, neuroendocrine markers, Bdnf, Cnr1, preclinical depression models, personalized neuromodulation, psychedelic research, biomarker-guided trialshttps://mindmedicinelaw.com/briefing/psychedelic-induced-personality-changes-evidence-and-gaps-global-2014-2024-20261013-50054The Psychedelic Journalen2026-10-14T22:06:37.426471+00:00Psychedelic-Induced Personality Changes: Evidence and Gaps (Global, 2014–2024)psychedelic research, personality trait change, neuroticism, systematic review, clinical trial design, regulatory considerations, mental health, psilocybin, LSD, ayahuascahttps://mindmedicinelaw.com/briefing/ketamine-for-trd-efficacy-differs-by-depression-subtype-and-trauma-20261013-50095The Psychedelic Journalen2026-10-14T22:06:15.711177+00:00Ketamine for TRD: Efficacy Differs by Depression Subtype and Traumaketamine, treatment-resistant depression, melancholic depression, depressive subtypes, childhood trauma, psychedelic-assisted therapy, clinical trials, precision psychiatry, biomedical ketamine, regulatory policyhttps://mindmedicinelaw.com/briefing/multimodal-imaging-validates-plasticity-markers-after-dmt-ketamine-in-uk-study-20261013-50112The Psychedelic Journalen2026-10-14T22:05:56.426871+00:00Multimodal Imaging Validates Plasticity Markers After DMT, Ketamine in UK Studysynaptic plasticity, pet imaging, dmt, ketamine, neuroimaging biomarkers, clinical trial endpoints, sv2a, diffusion weighted imaging, eeg, psychedelic researchhttps://mindmedicinelaw.com/briefing/pharmacist-training-for-psychedelic-medicine-u-s-readiness-grows-20261013-49829The Psychedelic Journalen2026-10-13T22:04:01.630882+00:00Pharmacist Training for Psychedelic Medicine: U.S. Readiness Growspharmacist training, psychedelic medicine, mdma, psilocybin, fda approval, pharmacy education, controlled substances, public health, regulatory readiness, patient safetyhttps://mindmedicinelaw.com/briefing/acute-basolateral-amygdala-dbs-shows-no-behavioral-impact-in-rats-20261012-50098The Psychedelic Journalen2026-10-14T22:09:19.779757+00:00Acute Basolateral Amygdala DBS Shows No Behavioral Impact in Ratsdeep brain stimulation, basolateral amygdala, preclinical safety, psychiatric neuromodulation, anxiety behavior, fear memory, rat models, translational research, psychedelic research, regulatory sciencehttps://mindmedicinelaw.com/briefing/oral-ketamine-assisted-psychotherapy-in-dnsd-case-report-and-clinical-implicatio-20261012-50100The Psychedelic Journalen2026-10-14T22:08:54.295379+00:00Oral Ketamine-Assisted Psychotherapy in DNSD: Case Report and Clinical Implicationsketamine-assisted psychotherapy, dissociative neurological symptom disorder, functional neurological disorder, case report, oral ketamine, mutism, treatment-resistant, psychedelic research, clinical evidence, off-label usehttps://mindmedicinelaw.com/briefing/psychedelic-assisted-therapy-in-ukraine-evidence-gaps-and-future-directions-20261012-50057The Psychedelic Journalen2026-10-14T22:08:36.319782+00:00Psychedelic-Assisted Therapy in Ukraine: Evidence, Gaps, and Future Directionspsychedelic-assisted therapy, psilocybin, mdma, lsd, ayahuasca, ukraine, clinical trials, mental health, policy, evidence gapshttps://mindmedicinelaw.com/briefing/standardizing-visual-snow-syndrome-diagnosis-implications-for-psychedelic-resear-20261012-50086The Psychedelic Journalen2026-10-14T22:08:14.259028+00:00Standardizing Visual Snow Syndrome Diagnosis: Implications for Psychedelic Researchvisual snow syndrome, diagnostic protocol, psychedelic research, adverse event monitoring, hallucinogen persisting perception disorder, cortical hyperexcitability, biomarker development, clinical trials, neurological safety, regulatory policyhttps://mindmedicinelaw.com/briefing/suzetrigine-analgesia-enhanced-by-nav1-7-null-opioid-mechanisms-preclinical-insi-20261012-50099The Psychedelic Journalen2026-10-14T22:07:51.743047+00:00Suzetrigine Analgesia Enhanced by Nav1.7 Null Opioid Mechanisms: Preclinical Insightssuzetrigine, nav1.7 sodium channel, endogenous opioid signaling, analgesia, pain management, preclinical research, rgs antagonists, inflammatory pain, clinical translationhttps://mindmedicinelaw.com/briefing/low-dose-esketamine-in-emergency-c-sections-rct-evidence-from-china-20261012-50097The Psychedelic Journalen2026-10-14T22:07:02.588531+00:00Low-Dose Esketamine in Emergency C-Sections: RCT Evidence from Chinaesketamine, emergency cesarean section, labor analgesia, randomized controlled trial, maternal hemodynamics, neonatal outcomes, acute pain management, obstetric anesthesia, clinical safetyhttps://mindmedicinelaw.com/briefing/ketamine-augmentation-strategies-in-trd-meta-analysis-insights-ncbi-2026-20261012-49998The Psychedelic Journalen2026-10-14T15:05:37.897068+00:00Ketamine Augmentation Strategies in TRD: Meta-Analysis Insights (NCBI, 2026)ketamine augmentation, treatment-resistant depression, systematic review, meta-analysis, clinical protocols, psychiatric policy, IV ketamine, adverse effects, personalized psychiatry, regulatory implicationshttps://mindmedicinelaw.com/briefing/psilocybin-assisted-mbsr-in-healthcare-workers-rct-mechanisms-and-policy-outlook-20261011-50244The Psychedelic Journalen2026-10-15T15:11:22.704436+00:00Psilocybin-Assisted MBSR in Healthcare Workers: RCT Mechanisms and Policy Outlookpsilocybin, mindfulness-based stress reduction, mystical experience, healthcare workers, depression, randomized controlled trial, mechanism of action, psychedelic-assisted therapy, clinical research, policy implications